查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1973877

人工智慧在癌症診斷市場分析及預測（至2035年）：按類型、產品類型、服務、技術、組件、應用、部署類型、最終用戶、模組和功能分類

AI In Cancer Diagnostics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Deployment, End User, Module, Functionality
出版日期: | 出版商: Global Insight Services | 英文 471 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，癌症診斷領域的人工智慧（AI）市場規模將從2024年的2.681億美元成長至23.601億美元，複合年成長率約為24.3%。癌症診斷領域的人工智慧市場涵蓋了利用人工智慧提高癌症檢測和診斷準確性和效率的各種技術。該市場整合了機器學習演算法、影像識別和預測分析等技術，以輔助病理學家和放射科醫生的工作。隨著對早期癌症檢測需求的不斷成長，人工智慧驅動的解決方案對於減少診斷錯誤和改善患者預後至關重要。人工智慧技術的進步、醫療保健投資的增加以及對個人化醫療日益成長的關注，都推動了該市場的成長。

由於機器學習和成像技術的進步，人工智慧在癌症診斷領域的市場預計將顯著成長。診斷成像領域是成長最快的細分市場，人工智慧驅動的成像工具能夠提高早期檢測率和診斷準確性。該領域主要由放射學和病理學領域的人工智慧應用主導，這些應用利用深度學習來增強診斷準確性。成長速度第二快的細分市場是基因組學。人工智慧分析複雜的基因數據正在革新個人化醫療。人工智慧驅動的基因組分析工具對於識別癌症生物標記和製定個人化治療方案至關重要。人工智慧在切片檢查分析中的應用也正在加速發展，能夠更深入地了解腫瘤特徵。此外，用於預測分析的人工智慧演算法對於預測預後和治療結果也變得至關重要。科技公司和醫療服務提供者之間的合作促進了創新，進一步加速了人工智慧在癌症診斷領域的應用。法規結構的完善和人們對人工智慧潛力的認知不斷提高，預計將推動未來市場擴張。

市場區隔
類型 影像學、基因組學、病理學、放射學、生物標記分析、臨床決策支持
產品 軟體、硬體、人工智慧平台、診斷設備
服務 諮詢服務、整合服務、維護服務、培訓和支持
科技 機器學習、深度學習、自然語言處理、電腦視覺
成分 人工智慧演算法、資料管理和使用者介面
應用 乳癌、肺癌、攝護腺癌、結腸癌
實施表格 雲端部署、本地部署、混合部署
最終用戶 醫院、診斷檢查室和研究實驗室
模組 數據分析、預測建模和風險評估
功能 檢測、預後和治療計劃

市場概況：

人工智慧癌症診斷市場正經歷著市場佔有率的動態變化。技術進步和創新診斷解決方案的推出，導致定價策略競爭日益激烈。近期推出的產品主要致力於提高診斷準確率和縮短診斷時間。各公司正利用人工智慧改善患者預後並簡化流程，進而推動全球醫療機構的快速採用。這一發展趨勢正為癌症診斷帶來變革性影響。人工智慧癌症診斷市場競爭異常激烈，IBM Watson Health 和 Google Health 等主要企業佔據市場主導地位。這些公司正大力投資研發，以維持其競爭優勢。監管的影響，尤其是在北美和歐洲，對塑造市場動態至關重要。遵守嚴格的標準能夠確保產品的有效性和安全性，從而增強消費者的信心。在技​​術創新和有利的法規環境的推動下，該市場正呈現出成長的跡象。

主要趨勢和促進因素：

由於技術進步和癌症發病率的上升，人工智慧在癌症診斷領域的市場正經歷強勁成長。關鍵趨勢包括將人工智慧與成像技術相結合，以提高癌症檢測的準確性和速度。機器學習演算法的進步，例如能夠分析複雜資料集的演算法，正在推動診斷準確性的提高和個人化治療方案的發展。對早期、精準癌症診斷日益成長的需求，正在推動人工智慧解決方案的普及。醫療機構擴大利用人工智慧來減少診斷錯誤並改善患者預後。大型資料集的日益豐富使得訓練更先進的人工智慧模型成為可能，進一步促進了市場成長。此外，科技公司與醫療機構之間的合作正在推動人工智慧在癌症診斷應用領域的創新。在醫療基礎設施不斷完善的發展中地區，新的機會正在湧現。能夠提供擴充性且經濟高效的人工智慧解決方案的公司，將佔據有利的市場佔有率。此外，監管機構對人工智慧驅動的診斷工具的支持，也促進了這些工具的普及，從而推動了市場的持續擴張。

限制與挑戰：

人工智慧在癌症診斷領域的市場面臨許多重大限制和挑戰。最重要的是，監管合規和核准流程依然嚴格且耗時，往往阻礙了市場准入和創新。此外，將人工智慧系統整合到現有醫療基礎設施中也存在技術和營運方面的挑戰，需要大量的投資和培訓。資料隱私和安全問題同樣不容忽視，因為敏感的病患資訊必須受到保護，免於外洩和濫用。此外，高品質、帶有標註的資料集嚴重短缺，而這些資料集對於訓練人工智慧演算法至關重要，這也限制了診斷工具的有效性和準確性。最後，來自醫療專業人員的抵觸情緒也是一個挑戰。他們可能對人工智慧的可靠性持懷疑態度，或擔心失去工作。總而言之，這些挑戰阻礙了人工智慧技術在癌症診斷領域的快速普及和發展，需要製定策略性的解決方案來克服這些挑戰。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 影像
    • 基因組學
    • 病理
    • 放射醫學
    • 生物標記分析
    • 臨床決策支持
  • 市場規模及預測：依產品分類
    • 軟體
    • 硬體
    • 人工智慧平台
    • 診斷設備
  • 市場規模及預測：依服務分類
    • 諮詢服務
    • 整合服務
    • 維護服務
    • 培訓和支持
  • 市場規模及預測：依技術分類
    • 機器學習
    • 深度學習
    • 自然語言處理
    • 電腦視覺
  • 市場規模及預測：依組件分類
    • 人工智慧演算法
    • 資料管理
    • 使用者介面
  • 市場規模及預測：依應用領域分類
    • 乳癌
    • 肺癌
    • 攝護腺癌
    • 大腸直腸癌
  • 市場規模及預測：依發展狀況
    • 基於雲端的
    • 本地部署
    • 混合
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 研究所
  • 按模組分類的市場規模和預測
    • 數據分析
    • 預測建模
    • 風險評估
  • 市場規模及預測：依功能分類
    • 偵測
    • 前景
    • 治療計劃

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Tempus
  • PathAI
  • Zebra Medical Vision
  • Freenome
  • CureMetrix
  • Ibex Medical Analytics
  • Deep Lens
  • Proscia
  • Oncora Medical
  • Enlitic
  • Owkin
  • Miramus
  • Lunit
  • Qure.ai
  • Aiforia
  • Kheiron Medical
  • Huron Digital Pathology
  • Viz.ai
  • Koios Medical
  • Aidence

第9章：關於我們

簡介目錄
Product Code: GIS33042

AI In Cancer Diagnostics Market is anticipated to expand from $268.1 million in 2024 to $2,360.1 million by 2034, growing at a CAGR of approximately 24.3%. The AI in Cancer Diagnostics Market encompasses technologies utilizing artificial intelligence to enhance the accuracy and efficiency of cancer detection and diagnosis. This market integrates machine learning algorithms, image recognition, and predictive analytics to aid pathologists and radiologists. As demand for early cancer detection rises, AI-driven solutions are pivotal in reducing diagnostic errors and improving patient outcomes. The market is poised for growth, driven by advancements in AI technology, increasing healthcare investments, and a growing emphasis on personalized medicine.

The AI in Cancer Diagnostics Market is poised for significant growth, driven by advancements in machine learning and imaging technologies. The imaging segment is the top-performing sub-segment, with AI-powered imaging tools enhancing early detection and diagnostic accuracy. Within this segment, radiology and pathology AI applications are leading, leveraging deep learning to improve diagnostic precision. The second highest performing sub-segment is the genomics segment, where AI is revolutionizing personalized medicine by analyzing complex genetic data. AI-driven genomic tools are crucial in identifying cancer biomarkers and tailoring treatment plans. The integration of AI in biopsy analysis is also gaining momentum, offering enhanced insights into tumor characteristics. Moreover, AI algorithms for predictive analytics are becoming indispensable, aiding in prognosis and treatment outcome predictions. The adoption of AI in cancer diagnostics is further propelled by collaborations between tech companies and healthcare providers, fostering innovation. Enhanced regulatory frameworks and increasing awareness of AI's potential are expected to drive future market expansion.

Market Segmentation
TypeImaging, Genomics, Pathology, Radiology, Biomarker Analysis, Clinical Decision Support
ProductSoftware, Hardware, AI Platforms, Diagnostic Devices
ServicesConsulting Services, Integration Services, Maintenance Services, Training and Support
TechnologyMachine Learning, Deep Learning, Natural Language Processing, Computer Vision
ComponentAI Algorithms, Data Management, User Interface
ApplicationBreast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer
DeploymentCloud-Based, On-Premises, Hybrid
End UserHospitals, Diagnostic Laboratories, Research Institutes
ModuleData Analysis, Predictive Modelling, Risk Assessment
FunctionalityDetection, Prognosis, Treatment Planning

Market Snapshot:

The AI in Cancer Diagnostics Market is witnessing a dynamic shift in market share. Pricing strategies are increasingly competitive, driven by technological advancements and the introduction of innovative diagnostic solutions. Recent product launches have demonstrated a focus on enhancing accuracy and reducing diagnostic time. Companies are leveraging AI to improve patient outcomes and streamline processes, which is fostering rapid adoption across healthcare institutions globally. This evolution is setting the stage for a transformative impact on cancer diagnostics. Competition in the AI in Cancer Diagnostics Market is intensifying, with key players like IBM Watson Health and Google Health leading the charge. These companies are investing heavily in research and development to maintain a competitive edge. Regulatory influences, particularly in North America and Europe, are crucial in shaping market dynamics. Compliance with stringent standards ensures product efficacy and safety, thereby boosting consumer trust. The market is poised for growth, driven by technological innovations and favorable regulatory environments.

Geographical Overview:

The AI in cancer diagnostics market is poised for substantial growth across diverse regions. North America leads the charge, propelled by its advanced healthcare infrastructure and robust AI research initiatives. The region's focus on early cancer detection and personalized medicine further augments this growth. Europe follows closely, with significant investments in AI-driven healthcare solutions. The continent's emphasis on regulatory frameworks ensures the safe integration of AI technologies in diagnostics. Asia Pacific is emerging as a vital growth pocket, driven by increasing cancer prevalence and technological advancements. Countries like China and India are at the forefront, investing heavily in AI research and healthcare innovation. These nations are poised to revolutionize cancer diagnostics with their rapid adoption of AI technologies. Meanwhile, Latin America and the Middle East & Africa are gradually recognizing the potential of AI in healthcare. These regions are beginning to invest in AI infrastructure, promising future growth in cancer diagnostics.

Key Trends and Drivers:

The AI in Cancer Diagnostics Market is experiencing robust growth due to technological advancements and increasing cancer prevalence. Key trends include the integration of AI with imaging technologies, enhancing the accuracy and speed of cancer detection. Machine learning algorithms are being developed to analyze complex datasets, improving diagnostic precision and personalized treatment planning. The demand for early and accurate cancer diagnosis is driving the adoption of AI solutions. Healthcare providers are increasingly leveraging AI to reduce diagnostic errors and improve patient outcomes. The growing availability of large datasets is enabling the training of more sophisticated AI models, further propelling market growth. Additionally, collaborations between technology companies and healthcare institutions are fostering innovation in AI applications for cancer diagnostics. Opportunities are emerging in developing regions where healthcare infrastructure is expanding. Companies that offer scalable and cost-effective AI solutions are well-positioned to capture market share. Furthermore, regulatory support for AI-driven diagnostic tools is enhancing their adoption, promising sustained market expansion.

Restraints and Challenges:

The AI in Cancer Diagnostics Market is confronted with several significant restraints and challenges. Foremost among these is the regulatory compliance and approval process, which remains stringent and time-consuming, often delaying market entry and innovation. Additionally, the integration of AI systems into existing healthcare infrastructure presents technical and operational difficulties, requiring substantial investment and training. Data privacy and security concerns also pose critical challenges, as sensitive patient information must be safeguarded against breaches and misuse. Furthermore, there is a notable scarcity of high-quality, annotated datasets necessary for training AI algorithms, which limits the efficacy and accuracy of diagnostic tools. Lastly, the market faces resistance from healthcare professionals who may be skeptical of AI's reliability and fear potential job displacement. These challenges collectively impede the rapid adoption and growth of AI technologies in cancer diagnostics, necessitating strategic solutions to overcome them.

Key Players:

Tempus, PathAI, Zebra Medical Vision, Freenome, CureMetrix, Ibex Medical Analytics, Deep Lens, Proscia, Oncora Medical, Enlitic, Owkin, Miramus, Lunit, Qure.ai, Aiforia, Kheiron Medical, Huron Digital Pathology, Viz.ai, Koios Medical, Aidence

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Module
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Imaging
    • 4.1.2 Genomics
    • 4.1.3 Pathology
    • 4.1.4 Radiology
    • 4.1.5 Biomarker Analysis
    • 4.1.6 Clinical Decision Support
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software
    • 4.2.2 Hardware
    • 4.2.3 AI Platforms
    • 4.2.4 Diagnostic Devices
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting Services
    • 4.3.2 Integration Services
    • 4.3.3 Maintenance Services
    • 4.3.4 Training and Support
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Machine Learning
    • 4.4.2 Deep Learning
    • 4.4.3 Natural Language Processing
    • 4.4.4 Computer Vision
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 AI Algorithms
    • 4.5.2 Data Management
    • 4.5.3 User Interface
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Breast Cancer
    • 4.6.2 Lung Cancer
    • 4.6.3 Prostate Cancer
    • 4.6.4 Colorectal Cancer
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 Cloud-Based
    • 4.7.2 On-Premises
    • 4.7.3 Hybrid
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Diagnostic Laboratories
    • 4.8.3 Research Institutes
  • 4.9 Market Size & Forecast by Module (2020-2035)
    • 4.9.1 Data Analysis
    • 4.9.2 Predictive Modelling
    • 4.9.3 Risk Assessment
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Detection
    • 4.10.2 Prognosis
    • 4.10.3 Treatment Planning

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Deployment
      • 5.2.1.8 End User
      • 5.2.1.9 Module
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Deployment
      • 5.2.2.8 End User
      • 5.2.2.9 Module
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Deployment
      • 5.2.3.8 End User
      • 5.2.3.9 Module
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Deployment
      • 5.3.1.8 End User
      • 5.3.1.9 Module
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Deployment
      • 5.3.2.8 End User
      • 5.3.2.9 Module
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Deployment
      • 5.3.3.8 End User
      • 5.3.3.9 Module
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Deployment
      • 5.4.1.8 End User
      • 5.4.1.9 Module
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Deployment
      • 5.4.2.8 End User
      • 5.4.2.9 Module
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Deployment
      • 5.4.3.8 End User
      • 5.4.3.9 Module
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Deployment
      • 5.4.4.8 End User
      • 5.4.4.9 Module
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Deployment
      • 5.4.5.8 End User
      • 5.4.5.9 Module
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Deployment
      • 5.4.6.8 End User
      • 5.4.6.9 Module
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Deployment
      • 5.4.7.8 End User
      • 5.4.7.9 Module
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Deployment
      • 5.5.1.8 End User
      • 5.5.1.9 Module
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Deployment
      • 5.5.2.8 End User
      • 5.5.2.9 Module
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Deployment
      • 5.5.3.8 End User
      • 5.5.3.9 Module
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Deployment
      • 5.5.4.8 End User
      • 5.5.4.9 Module
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Deployment
      • 5.5.5.8 End User
      • 5.5.5.9 Module
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Deployment
      • 5.5.6.8 End User
      • 5.5.6.9 Module
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Deployment
      • 5.6.1.8 End User
      • 5.6.1.9 Module
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Deployment
      • 5.6.2.8 End User
      • 5.6.2.9 Module
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Deployment
      • 5.6.3.8 End User
      • 5.6.3.9 Module
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Deployment
      • 5.6.4.8 End User
      • 5.6.4.9 Module
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Deployment
      • 5.6.5.8 End User
      • 5.6.5.9 Module
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Tempus
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 PathAI
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Zebra Medical Vision
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Freenome
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 CureMetrix
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Ibex Medical Analytics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Deep Lens
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Proscia
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Oncora Medical
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Enlitic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Owkin
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Miramus
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Lunit
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Qure.ai
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Aiforia
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Kheiron Medical
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Huron Digital Pathology
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Viz.ai
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Koios Medical
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Aidence
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us